The ability to detect low levels of circulating tumor DNA (ctDNA) can be significantly improved by first analyzing mutations identified through tumor genotyping, according to a new study in Science Translational Medicine. While ctDNA has proven useful for noninvasive cancer monitoring, detecting this genetic material in patients with low-volume or residual disease remains challenging.